Table 1 Clinicopathological characteristics and KRAS and BRAF mutations in LGSC
Clinicopathological characteristics | KRAS/BRAF gene | P-value | |
|---|---|---|---|
Mutation (n = 11) | Wild-type (n = 21) | ||
Age (years) | 0.106 | ||
< 45 | 1 (9.10%) | 9 (42.86%) | |
≥ 45 | 10 (90.90%) | 12 (57.14%) | |
FIGO stage | 1.000 | ||
I/II | 3 (27.27%) | 7 (33.33%) | |
III/IV | 8 (72.73%) | 14 (66.67%) | |
CA125 (U/ml) | 1.000 | ||
≤ 35 U/mL | 0 (0.00%) | 1 (4.76%) | |
> 35 U/mL | 11 (100.00%) | 20 (95.24%) | |
Tumor size(cm) | 0.442 | ||
< 10 | 5 (45.45%) | 6 (28.57%) | |
≥ 10 | 6 (54.55%) | 15 (71.43%) | |
Laterality | 0.053 | ||
Unilateral | 7 (63.64%) | 5 (23.81%) | |
Bilateral | 4 (36.36%) | 16 (76.19%) | |
Cytology | 0.703 | ||
Negative | 8 (72.73%) | 13 (61.90%) | |
Positive | 3 (27.27%) | 8 (38.10%) | |
Ascites | 0.441 | ||
Absent | 2 (18.18%) | 7 (33.33%) | |
Present | 9 (81.82%) | 14 (66.67%) | |
Ovarian surface involvement | 0.815 | ||
No | 3 (27.27%) | 8 (38.10%) | |
Yes | 7 (63.64%) | 11 (52.38%) | |
Unknown | 1 (9.10%) | 2 (9.52%) | |
Metastases | 1.000 | ||
No | 3 (27.27%) | 7 (33.33%) | |
Yes | 8 (72.73%) | 14 (66.67%) | |
Lymph node involvement | 0.392 | ||
No | 1 (9.10%) | 1 (4.76%) | |
Yes | 2 (18.18%) | 1 (4.76%) | |
Unknown | 8 (72.73%) | 19 (90.48%) | |